EA200901062A1 - Использование ингибиторов растворимой эпоксидгидролазы для предотвращения и лечения метаболического синдрома и соответствующих расстройств - Google Patents

Использование ингибиторов растворимой эпоксидгидролазы для предотвращения и лечения метаболического синдрома и соответствующих расстройств

Info

Publication number
EA200901062A1
EA200901062A1 EA200901062A EA200901062A EA200901062A1 EA 200901062 A1 EA200901062 A1 EA 200901062A1 EA 200901062 A EA200901062 A EA 200901062A EA 200901062 A EA200901062 A EA 200901062A EA 200901062 A1 EA200901062 A1 EA 200901062A1
Authority
EA
Eurasian Patent Office
Prior art keywords
metabolic syndrome
epoxydhydrolase
inhibitors
prevention
soluble
Prior art date
Application number
EA200901062A
Other languages
English (en)
Inventor
Хезэ Кей Уэбб Сюй
Original Assignee
Эрет Терэпьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эрет Терэпьютикс, Инк. filed Critical Эрет Терэпьютикс, Инк.
Publication of EA200901062A1 publication Critical patent/EA200901062A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Раскрываются соединения, композиции и способы подавления начала развития метаболического синдрома и лечения соответствующих расстройств у больного, нуждающегося в такой терапии.
EA200901062A 2007-01-29 2008-01-28 Использование ингибиторов растворимой эпоксидгидролазы для предотвращения и лечения метаболического синдрома и соответствующих расстройств EA200901062A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88712407P 2007-01-29 2007-01-29
PCT/US2008/052226 WO2008094869A1 (en) 2007-01-29 2008-01-28 Soluble epoxide hydrolase inhibitors for treatment of metabolic syndrome and related disorders

Publications (1)

Publication Number Publication Date
EA200901062A1 true EA200901062A1 (ru) 2009-12-30

Family

ID=39400919

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200901062A EA200901062A1 (ru) 2007-01-29 2008-01-28 Использование ингибиторов растворимой эпоксидгидролазы для предотвращения и лечения метаболического синдрома и соответствующих расстройств

Country Status (13)

Country Link
US (1) US20080221105A1 (ru)
EP (1) EP2124917A1 (ru)
JP (1) JP2010516787A (ru)
KR (1) KR20090111319A (ru)
CN (1) CN101594858A (ru)
AU (1) AU2008210730A1 (ru)
BR (1) BRPI0807829A2 (ru)
CA (1) CA2675450A1 (ru)
EA (1) EA200901062A1 (ru)
IL (1) IL199655A0 (ru)
MX (1) MX2009008073A (ru)
TW (1) TW200932224A (ru)
WO (1) WO2008094869A1 (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090197916A1 (en) * 2007-01-29 2009-08-06 Arete Therapeutics, Inc Soluble epoxide hydrolase inhibitors for treatment of metabolic syndrome and related disorders
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US8809552B2 (en) * 2011-11-01 2014-08-19 Hoffmann-La Roche Inc. Azetidine compounds, compositions and methods of use
CN113402447B (zh) * 2021-06-22 2022-10-18 沈阳药科大学 一种sEH抑制剂或其药学上可接受的组合物及其制备方法和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6174695B1 (en) * 1997-08-12 2001-01-16 The Regents Of The University Of California Epoxide hydrolase inhibitor methods
MXPA03011681A (es) * 2001-06-29 2004-03-19 Boehringer Ingelheim Pharma Uso de inhibidores de epoxido hidrolasa soluble, para tratar enfermedades relacionadas con la enfermedad cardiovascular.
DE10135027A1 (de) * 2001-07-18 2003-02-06 Solvay Pharm Gmbh Verwendung Trifluoracetylalkyl-substituierter Phenyl-, Phenol- und Benzoylderivate in der Behandlung und/oder Prophylaxe von Obestias und deren Begleit- und/oder Folgeerkrankungen
US20050026844A1 (en) * 2003-04-03 2005-02-03 Regents Of The University Of California Inhibitors for the soluble epoxide hydrolase
US20050164951A1 (en) * 2003-04-03 2005-07-28 The Regents Of The University Of California Inhibitors for the soluble epoxide hydrolase
US20060148744A1 (en) * 2004-09-23 2006-07-06 Regents Of The University Of California Use of cis-epoxyeicosantrienoic acids and inhibitors of soluble epoxide hydrolase to reduce damage from stroke
CA2584342C (en) * 2004-10-20 2013-04-30 The Regents Of The University Of California Improved inhibitors for the soluble epoxide hydrolase
US7951831B2 (en) * 2005-01-10 2011-05-31 The Regents Of The University Of California Use of inhibitors of soluble epoxide hydrolase to synergize activity of COX and 5-LOX inhibitors
JP2008540433A (ja) * 2005-05-06 2008-11-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 可溶性エポキシドヒドロラーゼインヒビター及びその使用方法
CA2608243A1 (en) * 2005-05-06 2006-11-16 Boehringer Ingelheim International Gmbh Acyl hydrazones for treating cardiovascular diseases
WO2006133257A2 (en) * 2005-06-06 2006-12-14 The Regents Of The University Of California Use of cis-epoxyeicosatrienoic acids and inhibitors of soluble epoxide hydrolase to reduce cardiomyopathy
KR20080021082A (ko) * 2005-06-20 2008-03-06 쉐링 코포레이션 히스타민 ｈ3 길항제로서 유용한 피페리딘 유도체
TW200808723A (en) * 2006-03-13 2008-02-16 Univ California Conformationally restricted urea inhibitors of soluble epoxide hydrolase

Also Published As

Publication number Publication date
IL199655A0 (en) 2010-04-15
JP2010516787A (ja) 2010-05-20
AU2008210730A1 (en) 2008-08-07
WO2008094869A1 (en) 2008-08-07
CA2675450A1 (en) 2008-08-07
BRPI0807829A2 (pt) 2014-08-05
US20080221105A1 (en) 2008-09-11
KR20090111319A (ko) 2009-10-26
TW200932224A (en) 2009-08-01
EP2124917A1 (en) 2009-12-02
MX2009008073A (es) 2009-08-12
CN101594858A (zh) 2009-12-02

Similar Documents

Publication Publication Date Title
EA201000016A1 (ru) Способы и композиции для лечения рака, опухолей и нарушений, связанных с опухолями
EA201791669A2 (ru) Новые терапевтические подходы в лечении смт и связанных с ней расстройств
EA200970932A1 (ru) Способы лечения с применением пиридопиримидиноновых ингибиторов pi3k альфа
EA201270184A1 (ru) Лечение расстройств печени ингибиторами pi3k
EA200970542A1 (ru) ИНГИБИТОРЫ ДЕЙСТВИЯ Akt
MX361467B (es) Compuestos de isoindolina para uso en el tratamiento de cancer.
EA200970935A1 (ru) Способы лечения с применением хинаксолиновых ингибиторов pi3k-альфа
EA201100971A1 (ru) Производные пиримидининдола для лечения злокачественного новообразования
WO2015095819A3 (en) Cancer treatment using combinations of erk and raf inhibitors
NO20074999L (no) Metode og preparat for behandling av perifere vaskulaere sykdommer
EA200801897A1 (ru) Ингибиторы mnk2 на основе 8-гетероарилпурина для лечения метаболических нарушений
DK1933833T3 (da) Terapi til behandling af overaktiv blære
NO20065847L (no) Difenylimidazopyrimidiner og -imidazolaminer som inhibitorer av B-sekretase
NO20083202L (no) ANG2- og VEFG-inhibitorkombinasjoner
EA200600414A1 (ru) ПРОИЗВОДНЫЕ БОРОНОВОЙ КИСЛОТЫ (ВАРИАНТЫ), ПРОМЕЖУТОЧНЫЕ СОЕДИНЕНИЯ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ, КОМПОЗИЦИЯ ДЛЯ ИНГИБИРОВАНИЯ АКТИВНОСТИ NF-kB И ДЕГРАДАЦИИ БЕЛКА И СПОСОБЫ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ (ВАРИАНТЫ)
EA201490814A1 (ru) Лечение злокачественной опухоли ингибиторами tor-киназы
MY173994A (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
EA200900819A1 (ru) Хиназолины для ингибирования pdk1
MX343135B (es) Compuestos de tipo fumagilol y métodos de realización y uso de los mismos.
WO2008148074A3 (en) Inhibitors of mtor and methods of treatment using same
MX2008011633A (es) Aminoquinolonas como inhibidores de gsk-3.
EA200900571A1 (ru) Композиции chk1 ингибиторов
EA201690745A1 (ru) Способы лечения и предотвращения болезни &#34;трансплантат против хозяина&#34;
MX350046B (es) Tratamientos para trastornos gastrointestinales.
EA200701995A1 (ru) Способы уменьшения кальцификации